207 related articles for article (PubMed ID: 16406207)
1. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.
Keogh JP; Kunta JR
Eur J Pharm Sci; 2006 Apr; 27(5):543-54. PubMed ID: 16406207
[TBL] [Abstract][Full Text] [Related]
2. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
Rautio J; Humphreys JE; Webster LO; Balakrishnan A; Keogh JP; Kunta JR; Serabjit-Singh CJ; Polli JW
Drug Metab Dispos; 2006 May; 34(5):786-92. PubMed ID: 16455806
[TBL] [Abstract][Full Text] [Related]
3. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.
Acharya P; O'Connor MP; Polli JW; Ayrton A; Ellens H; Bentz J
Drug Metab Dispos; 2008 Feb; 36(2):452-60. PubMed ID: 17967933
[TBL] [Abstract][Full Text] [Related]
4. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
5. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1).
Tanigawara Y; Okamura N; Hirai M; Yasuhara M; Ueda K; Kioka N; Komano T; Hori R
J Pharmacol Exp Ther; 1992 Nov; 263(2):840-5. PubMed ID: 1359120
[TBL] [Abstract][Full Text] [Related]
6. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
7. Several major antiepileptic drugs are substrates for human P-glycoprotein.
Luna-Tortós C; Fedrowitz M; Löscher W
Neuropharmacology; 2008 Dec; 55(8):1364-75. PubMed ID: 18824002
[TBL] [Abstract][Full Text] [Related]
8. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.
Fenner KS; Troutman MD; Kempshall S; Cook JA; Ware JA; Smith DA; Lee CA
Clin Pharmacol Ther; 2009 Feb; 85(2):173-81. PubMed ID: 18987624
[TBL] [Abstract][Full Text] [Related]
9. Potential role for human P-glycoprotein in the transport of lacosamide.
Zhang C; Chanteux H; Zuo Z; Kwan P; Baum L
Epilepsia; 2013 Jul; 54(7):1154-60. PubMed ID: 23551115
[TBL] [Abstract][Full Text] [Related]
10. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
He H; Lyons KA; Shen X; Yao Z; Bleasby K; Chan G; Hafey M; Li X; Xu S; Salituro GM; Cohen LH; Tang W
Xenobiotica; 2009 Sep; 39(9):687-93. PubMed ID: 19569734
[TBL] [Abstract][Full Text] [Related]
11. Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin.
Sandage B; Sabounjian L; Shipley J; Profy A; Lasseter K; Fox L; Harnett M
J Clin Pharmacol; 2006 Jul; 46(7):776-84. PubMed ID: 16809803
[TBL] [Abstract][Full Text] [Related]
12. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
13. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux.
Hayeshi R; Masimirembwa C; Mukanganyama S; Ungell AL
Eur J Pharm Sci; 2006 Sep; 29(1):70-81. PubMed ID: 16846720
[TBL] [Abstract][Full Text] [Related]
14. Ultrafast mass spectrometry based bioanalytical method for digoxin supporting an in vitro P-glycoprotein (P-gp) inhibition screen.
Wagner AD; Kolb JM; Ozbal CC; Herbst JJ; Olah TV; Weller HN; Zvyaga TA; Shou WZ
Rapid Commun Mass Spectrom; 2011 May; 25(9):1231-40. PubMed ID: 21488121
[TBL] [Abstract][Full Text] [Related]
15. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction.
Collett A; Tanianis-Hughes J; Carlson GL; Harwood MD; Warhurst G
Eur J Pharm Sci; 2005 Dec; 26(5):386-93. PubMed ID: 16153812
[TBL] [Abstract][Full Text] [Related]
16. Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux.
Jutabha P; Wempe MF; Anzai N; Otomo J; Kadota T; Endou H
Pharmacol Res; 2010 Jan; 61(1):76-84. PubMed ID: 19631272
[TBL] [Abstract][Full Text] [Related]
17. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
Larsen UL; Hyldahl Olesen L; Guldborg Nyvold C; Eriksen J; Jakobsen P; Østergaard M; Autrup H; Andersen V
Scand J Clin Lab Invest; 2007; 67(2):123-34. PubMed ID: 17365992
[TBL] [Abstract][Full Text] [Related]
18. The complexity of intestinal absorption and exsorption of digoxin in rats.
Yao HM; Chiou WL
Int J Pharm; 2006 Sep; 322(1-2):79-86. PubMed ID: 16781832
[TBL] [Abstract][Full Text] [Related]
19. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
20. Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein.
Iwaki K; Sakaeda T; Kakumoto M; Nakamura T; Komoto C; Okamura N; Nishiguchi K; Shiraki T; Horinouchi M; Okumura K
J Pharm Pharmacol; 2006 Dec; 58(12):1617-22. PubMed ID: 17331325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
